CL2021003342A1 - Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa. - Google Patents

Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa.

Info

Publication number
CL2021003342A1
CL2021003342A1 CL2021003342A CL2021003342A CL2021003342A1 CL 2021003342 A1 CL2021003342 A1 CL 2021003342A1 CL 2021003342 A CL2021003342 A CL 2021003342A CL 2021003342 A CL2021003342 A CL 2021003342A CL 2021003342 A1 CL2021003342 A1 CL 2021003342A1
Authority
CL
Chile
Prior art keywords
pyrazole compounds
disubstituted pyrazole
ketohexokinase inhibitors
formula
ketohexokinase
Prior art date
Application number
CL2021003342A
Other languages
English (en)
Inventor
David Andrew Coates
Steven Marc Massey
Timothy Barrett Durham
Richard Duane Johnston
Patrick Gianpietro Spinazze
Douglas Richard Stack
James Lee Toth
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2021003342A1 publication Critical patent/CL2021003342A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

La presente invención proporciona un compuesto de la Fórmula I, o una sal farmacéuticamente aceptable del mismo, y el uso de los compuestos de la Fórmula I para el tratamiento de afecciones metabólicas, tales como la diabetes mellitus tipo 2, la insuficiencia cardíaca, la enfermedad renal diabética y la esteatohepatitis no alcohólica.
CL2021003342A 2019-06-17 2021-12-14 Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa. CL2021003342A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962862382P 2019-06-17 2019-06-17
US202062975887P 2020-02-13 2020-02-13

Publications (1)

Publication Number Publication Date
CL2021003342A1 true CL2021003342A1 (es) 2022-09-09

Family

ID=71950812

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003342A CL2021003342A1 (es) 2019-06-17 2021-12-14 Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa.

Country Status (22)

Country Link
US (2) US11124500B2 (es)
EP (1) EP3983404B1 (es)
JP (2) JP6986653B2 (es)
KR (1) KR20220008882A (es)
CN (1) CN114008036A (es)
AU (1) AU2020295979A1 (es)
BR (1) BR112021023153A2 (es)
CA (1) CA3143490C (es)
CL (1) CL2021003342A1 (es)
CO (1) CO2021016870A2 (es)
CR (1) CR20210600A (es)
EC (1) ECSP21091203A (es)
ES (1) ES2961283T3 (es)
IL (1) IL288350A (es)
JO (1) JOP20210329A1 (es)
MA (1) MA56208A (es)
MX (1) MX2021015325A (es)
PE (1) PE20220377A1 (es)
TW (1) TWI750685B (es)
UA (1) UA126847C2 (es)
WO (1) WO2020257171A1 (es)
ZA (1) ZA202109067B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021129817A1 (zh) * 2019-12-25 2021-07-01 南京明德新药研发有限公司 具有果糖激酶(khk)抑制作用的嘧啶类化合物
US20240067633A1 (en) * 2020-12-25 2024-02-29 Sichuan Haisco Pharmaceutical Co., Ltd. Ketohexokinase inhibitor and use thereof
US20230079863A1 (en) * 2021-03-29 2023-03-16 Gilead Sciences, Inc. Khk inhibitors
WO2022211595A1 (ko) * 2021-04-01 2022-10-06 주식회사 엘지화학 옥사디아졸 화합물 및 이를 포함하는 약제학적 조성물
WO2023121378A1 (ko) * 2021-12-24 2023-06-29 주식회사 엘지화학 (s)-2-(2-메틸아제티딘-1-일)피리미딘 유도체 및 이를 포함하는 약제학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101111247B1 (ko) * 2009-07-17 2012-06-12 한국과학기술연구원 Ｒｏｓ 카이네이즈 저해활성을 갖는 피라졸 화합물
US10093668B2 (en) * 2015-10-28 2018-10-09 Northwestern University Substituted aromatic N-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (Mnk1) and 2 (Mnk2)
SI3397631T1 (sl) * 2015-12-29 2022-01-31 Pfizer Inc. Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze
TWI714231B (zh) * 2018-09-04 2020-12-21 美商美國禮來大藥廠 2,6-二胺基吡啶化合物

Also Published As

Publication number Publication date
WO2020257171A1 (en) 2020-12-24
BR112021023153A2 (pt) 2022-01-04
TW202112768A (zh) 2021-04-01
JP2022031816A (ja) 2022-02-22
US20200392118A1 (en) 2020-12-17
MX2021015325A (es) 2022-01-18
ES2961283T3 (es) 2024-03-11
EP3983404B1 (en) 2023-08-09
PE20220377A1 (es) 2022-03-16
JOP20210329A1 (ar) 2023-01-30
CR20210600A (es) 2022-01-11
US11124500B2 (en) 2021-09-21
JP7221367B2 (ja) 2023-02-13
UA126847C2 (uk) 2023-02-08
IL288350A (en) 2022-01-01
CN114008036A (zh) 2022-02-01
MA56208A (fr) 2022-04-20
CA3143490C (en) 2024-03-05
ZA202109067B (en) 2023-06-28
EP3983404A1 (en) 2022-04-20
KR20220008882A (ko) 2022-01-21
JP2021525793A (ja) 2021-09-27
TWI750685B (zh) 2021-12-21
ECSP21091203A (es) 2022-01-31
CO2021016870A2 (es) 2022-01-17
JP6986653B2 (ja) 2021-12-22
CA3143490A1 (en) 2020-12-24
US20220017496A1 (en) 2022-01-20
AU2020295979A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
CL2021003342A1 (es) Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa.
ECSP21015267A (es) Compuestos de 2,6-diaminopiridina
DOP2021000273A (es) Agonistas del receptor del péptido-1 similar al glucagón
CL2023002682A1 (es) Uso de inhibidores de ehmt2 para tratar trastornos sanguíneos
CO2020014586A2 (es) Compuestos
CL2013001558A1 (es) El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico.
AR117814A1 (es) Compuestos moduladores de fxr (nr1h4)
CO2022017226A2 (es) Antagonistas del receptor de lpa y usos de los mismos
AR111178A1 (es) Inhibidor de la quinasa reguladora de la señal de apoptosis
BR112019007576A2 (pt) compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
BR112016029065A2 (pt) ?composto, composição farmacêutica, e, uso de um composto?
CO2023001407A2 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
MX2020008523A (es) Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5).
PH12021550248A1 (en) Borate of azetidine derivative
AR102248A1 (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes
EA202192957A1 (ru) Дизамещенные пиразольные соединения в качестве ингибиторов кетогексокиназы
CO2020001514A2 (es) Composición farmacéutica para la prevención o el tratamiento de enfermedades cardiovasculares acompañadas por diabetes, que incluye amlodipino, losartán y rosuvastatina, y preparación compuesta que incluye los mismos
CO2024001017A2 (es) Compuestos terapéuticos y procedimientos
AR109895A1 (es) Compuestos cíclicos de péptido tirosina tirosina como moduladores de neuropéptido y receptores
AR117669A1 (es) Métodos para tratar sujetos que padecen diabetes con enfermedad renal crónica
BR112022008831A2 (pt) Uso de composto na prevenção ou tratamento de doença de enxerto versus hospedeiro
UY30825A1 (es) Ureas n-[3-[4-(4-cianofenil)piperidina-1-carbonil]fenil]-n'-(alquilo sustituido)sustituidas, procedimiento para la preparacion y aplicaciones